Jänne P.A.Baik C.Su W.-C.Johnson M.L.Hayashi H.Nishio M.Kim D.-W.Koczywas M.Gold K.A.Steuer C.E.Murakami H.CHIH-HSIN YANGKim S.-W.Vigliotti M.Shi R.Qi Z.Qiu Y.Zhao L.Sternberg D.Yu C.Yu H.A.2022-08-102022-08-1020222159-8290https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122457308&doi=10.1158%2f2159-8290.CD-21-0715&partnerID=40&md5=a49caf760e8f030ab180a8837990a0e6https://scholars.lib.ntu.edu.tw/handle/123456789/616494[SDGs]SDG3Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancerjournal article10.1158/2159-8290.CD-21-0715345483092-s2.0-85122457308